Bridge Biotherapeutics (KQ288330), a South Korea-based clinical-stage biotech company, announced on Tuesday that it has entered a research collaboration with Dr. Raul Torres's Lab at the University of Colorado School of Medicine.

The partnership is to concentrate on exploring the potential of BBT-877, a novel autotaxin (ATX) inhibitor, as an immuno-oncology treatment for cancer.

Throughout his earlier and ongoing research, Dr Raul Torres, professor of Immunology and Microbiology at the University of Colorado School of Medicine, has shown that lysophosphatidic acid (LPA) plays a role in modulating CD8 T cell immunosurveillance and metabolism, ultimately disrupting the body's anti-tumour immunity.

According to the terms of the collaboration, Bridge Biotherapeutics is to provide financial support and access to BBT-877, while Dr Raul Torres's Lab is to contribute its expertise in immunology and cancer biology. Both parties will together conduct preclinical studies to assess the therapeutic potential of BBT-877 in improving anti-tumour immunity.